(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.87%
@ $93.66
Išleistas: 26 bal. 2024 @ 21:20
Grąža: -0.70%
Ankstesnis signalas: bal. 25 - 19:08
Ankstesnis signalas:
Grąža: 3.76 %
Live Chart Being Loaded With Signals
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 710 386 |
Vidutinė apimtis | 805 482 |
Rinkos kapitalizacija | 5.69B |
EPS | $0 ( 2024-02-15 ) |
Kita pelno data | ( $-1.640 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.11 |
ATR14 | $4.51 (4.85%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Landsittel Michael | Buy | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Stock Option (Right to Buy) |
2024-03-07 | Albers Jeffrey W. | Sell | 11 033 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
36.49 |
Last 100 transactions |
Buy: 596 437 | Sell: 283 237 |
Tūris Koreliacija
Blueprint Medicines Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ACBA | 0.958 |
MANH | 0.953 |
PUCK | 0.951 |
VIRI | 0.949 |
GXII | 0.947 |
AEAC | 0.946 |
ESLT | 0.946 |
RAM | 0.946 |
IVCB | 0.945 |
SKYW | 0.945 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
PEAR | -0.951 |
VORB | -0.949 |
INFN | -0.934 |
MKTX | -0.931 |
BHTG | -0.928 |
FEMY | -0.927 |
IVAC | -0.926 |
EDUC | -0.926 |
TRIT | -0.925 |
OBNK | -0.924 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Blueprint Medicines Corp Koreliacija - Valiuta/Žaliavos
Blueprint Medicines Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $249.38M |
Bruto pelnas: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2023 |
Pajamos: | $249.38M |
Bruto pelnas: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2022 |
Pajamos: | $204.04M |
Bruto pelnas: | $186.22M (91.27 %) |
EPS: | $-9.35 |
FY | 2021 |
Pajamos: | $180.08M |
Bruto pelnas: | $162.15M (90.04 %) |
EPS: | $-11.81 |
Financial Reports:
No articles found.
Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.